ArticleScientific reports2025
Correlation of FSTL1 and its paralogs with body composition in adult survivors of childhood cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective, cross-sectional study investigated the relationship between body composition and circulating plasma levels of follistatin-like proteins (FSTLs; FSTL1, FSTL4, and FSTL5) in adult survivors of childhood cancer. This is the first study to investigate the association between plasma levels of FSTL4, FSTL5 and skeletal muscle mass. The cohort consisted of 61 CCS (26 females and 35 males) aged 18-36 years (mean age 24.6 ± 4.4 years) who were followed up at the Long-Term Follow-Up Clinic of St. Anne's Hospital in Brno, Czech Republic. The mean age at diagnosis was 10.9 ± 4.9 years, and the mean time after treatment was 12.0 ± 5.1 years. Body composition was assessed using anthropometric indicators and bioelectrical impedance analysis (BIA; InBody 370). Plasma FSTL levels were quantified using commercially available ELISA kits. Correlations were examined by linear regression analysis. A significant negative correlation was found between the FSTL1 plasma level and body fat mass index (BFMI), and a significant positive correlation was observed between FSTL1 and skeletal muscle mass index (SMI). Our results suggest that FSTL1 may be a potential indicator of adiposity and skeletal muscle loss in CCS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.